Late Clinical Events Associated With COVID-19 Infection (COCO-LATE)
Late Clinical Events Associated With COVID-19 Infection: Multicenter Cohort
Several publications document the occurrence of symptoms that persist or occur late.
The identification of the observed clinical manifestations and their clinical and paraclinical description are essential to better understand the natural evolution of COVID-19, to clarify the pathophysiological mechanism of these possible late manifestations, and to identify potential management options for patients.
Since this type of event is infrequent, a large-scale national multicenter cohort study focusing on symptomatic patients is needed.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Several publications document the occurrence of symptoms that persist or occur late, more than 3 weeks after the first clinical manifestations of an SARS-COV2 infection. These manifestations may be related to thromboembolic or inflammatory complications, superinfections, or other mechanisms not yet well understood, including potentially related to the persistence of SARS-COV2. The identification of the observed clinical manifestations and their clinical and paraclinical description are essential to better understand the natural evolution of COVID-19, to clarify the pathophysiological mechanism of these possible late manifestations, and to identify potential management options for patients.
Since this type of event is infrequent, a large-scale national multicenter cohort study focusing on symptomatic patients is needed. In parallel, the prevalence of the main symptoms observed more than 3 weeks after the onset of a COVID-19 will be estimated through partnerships with existing cohort studies in the general population or in the population followed for COVID-19, still symptomatic or not at 3 weeks of infection.
Longitudinal implementation of bio-libraries will allow this cohort to also constitute a bridge between clinicians and researchers.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Olivier ROBINEAU, MD PhD
- Número de telefone: 0320694949
- E-mail: orobineau@ch-tourcoing.fr
Locais de estudo
-
-
-
Auxerre, França
- Recrutamento
- CH Auxerre
-
Caen, França
- Recrutamento
- CHU Caen
-
Lille, França
- Recrutamento
- CHRU Lille
-
Melun, França
- Recrutamento
- CH Melun Marc Jacquet
-
Nemours, França
- Recrutamento
- CH Sud Seine et Marne
-
Paris, França
- Ainda não está recrutando
- AP-HP Hôpital Hôtel-Dieu
-
Saint-Priest-en-Jarez, França
- Recrutamento
- CHU de Saint-Etienne
-
Tourcoing, França
- Recrutamento
- CH Tourcoing
-
Tours, França
- Recrutamento
- Chru Tours
-
Vandœuvre-lès-Nancy, França
- Recrutamento
- CHRU NANCY
-
Vannes, França
- Recrutamento
- Centre Hospitalier Bretagne Atlantique
-
-
-
-
-
Cayenne, Guiana Francesa
- Recrutamento
- CH André Rosemon de Cayenne
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
History of symptomatic CoV-2-SARS infection as defined by :
o Positive RT-PCR SARS-CoV-2 RT-PCR result OR positive SARS-CoV-2 serology
o Associated with at least one event : x Anosmia occurring after February 2020 x OR COVID 19 evocative scanner x OR ≥ 2 contemporary symptoms of the virological sample from: asthenia, cough, dyspnea, fever, myalgia, dysgeusia, diarrhea AND not present prior to diagnosis
- AND persistence of at least one symptom present in the first 3 weeks of a COVID-19, more than 8 weeks away from the first symptoms of COVID-19. OR late onset of at least one new symptom a minimum of 3 weeks and a maximum of 6 months after the first symptoms of a CoV-2 SARS infection.
- First symptoms less than 6 months old on the day of inclusion
- To benefit from a State Health Insurance or Medical Aid plan
- Have signed an informed consent for inclusion.
Exclusion Criteria:
- Minor patient
- Patient under protection of justice
Patient who required intensive care management :
- more than 5 days
- OR requiring orotracheal intubation
- OR having required high flow ventilation (optiflow)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Standardized clinical and paraclinical follow-up
Standardized clinical and paraclinical follow-up will be offered in one of the referring investigator centers. Patients will be able to benefit from additional biological samples. Questionnaires will be completed by the patient or with the help of clinical research staff in paper format. All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID. Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits. Total serum, plasma and naso-paaryngeal samples will be collected. |
Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.
Total serum, plasma samples will be collected
All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Clinical description of asthenia
Prazo: At the end od the study, an average of 22 months
|
Describe the frequence of asthenia between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
|
Clinical description of dyspnea
Prazo: At the end od the study, an average of 22 months
|
Frequence of dyspnea between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
|
Clinical description of thoracic disorders
Prazo: At the end od the study, an average of 22 months
|
Frequence of thoracic disorders between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
|
Clinical description of neurological disorders
Prazo: At the end od the study, an average of 22 months
|
Frequence of neurological disorders between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
|
Clinical description of anosmia
Prazo: At the end od the study, an average of 22 months
|
Frequence of anosmia disorders between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Olivier ROBINEAU, MD PhD, CH Tourcoing
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- RIPH_2020_09
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .